Morning trading August 24, page-18

CYP
ASX ANNOUNCEMENT 24 August 2020
Patient Enrolment Opens in COVID-19 Clinical Trial
Melbourne, Australia; 24 August 2020: Cynata Therapeutics Limited (ASX: CYP), a leading clinical-stage
biotechnology company specialising in cell therapeutics, is pleased to announce that the MEND (MEseNchymal
coviD-19) Trial is now open for patient enrolment. Following ethics committee approval (as announced on
8 May 2020), this important step representsthe formal commencement of this clinical trial. The MEND Trial will
investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted
to intensive care with COVID-19.
Dr. Kilian Kelly, Cynata’s COO, said:
“The opening of enrolment of this clinical trial is a major achievement for Cynata. The trial builds on the solid
pre-clinical foundations for the use of our Cymerus MSC technology in respiratory diseases, including acute
respiratory distresssyndrome (ARDS), as well as cytokine release syndrome and sepsis, all of which are hallmarks
of critically ill COVID-19 patients.”
“Cynata’s proprietary Cymerus technology uniquely enables the manufacture at scale of a consistent and robust
MSC product without the substantial functional heterogeneity, i.e. lack of consistency, that has been observed
between MSC batches derived from different donors. We look forward to advancing this clinical trial to
investigate the potential benefits our MSCs could have to treat patientsin dire need during this global pandemic.”